Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means the agency’s own highest classification or reported deaths or serious injuries, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
Wells Pharmacy Network is recalling Estradiol 3 mg Pellets because they may be superpotent or subpotent. Consumers should stop using the product.
Wells Pharmacy Network is recalling Testosterone 12.5 mg Pellets because they were found to be superpotent or subpotent.
Wells Pharmacy Network is recalling Estradiol 12.5 mg Pellets because they may be superpotent or subpotent. Consumers should stop using the product.
Wells Pharmacy Network is recalling Testosterone Cholesterol 100 mg pellets because they were found to be superpotent or subpotent.
Mylan Institutional, Inc. is recalling specific lots of Clonazepam Tablets, USP, 0.5 mg because they failed impurity specifications.
Mylan Institutional is recalling specific lots of Clonazepam 1.0 mg tablets because a known impurity exceeded specification limits during stability testing.
Taro Pharmaceuticals is recalling 17,100 kits of Kamedis Bio-Herbal Dandruff Care System because the active ingredient, zinc pyrithione, was found to be subpotent.
PharMEDium Services is recalling specific vials of Succinylcholine Chloride because a portion of the batch was compounded outside of validated process media, raising sterility concerns.
Akorn Inc. is recalling 29,972 bottles of 5% Sodium Chloride Ophthalmic Solution because the product concentration is less than the labeled amount.
Par Pharmaceutical is recalling Gildess 1.5/30 tablets because they contain subpotent levels of ethinyl estradiol. The recall covers specific lots distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess 1/20 tablets because they contain subpotent levels of ethinyl estradiol. The recall covers 393,981 tablets distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess 24 FE 1.5/30 oral contraceptives because the ethinyl estradiol component is subpotent. The recall covers 44,127 tablets distributed nationwide and in Puerto Rico.
Taro Pharmaceuticals is recalling specific lots of Desoximetasone Cream 0.05% because they failed stability specifications for homogeneity.
Taro Pharmaceuticals is recalling specific lots of Desoximetasone Cream 0.25% because they failed stability tests for moderate separation.
Par Pharmaceutical is recalling Gildess FE 1/20 tablets because the ethinyl estradiol component is subpotent. The recall covers 822,009 tablets distributed nationwide and in Puerto Rico.
Actavis is recalling 15,984 bottles of Ramipril Capsules because they were labeled with an incorrect expiration date of 03/18 instead of 09/17.
Par Pharmaceutical is recalling Gildess FE 1.5/30 tablets because they may contain subpotent levels of ethinyl estradiol.
Boehringer Ingelheim is recalling 2,562 bottles of 75 mg Persantine tablets because 50 mg tablets were found inside the bottles.
Boehringer Ingelheim is recalling 6,400 bottles of 75 mg Dipyridamole tablets because 50 mg Persantine tablets were found inside the bottles.
Janssen Ortho L.L.C. is recalling Invokamet tablets because Xarelto prescribing information outserts may be affixed to the bottles instead of the correct Invokamet inserts.
SOS Telecom Inc. is recalling Super Samurai-X dietary supplements because FDA testing found undeclared sildenafil and/or its analogs.
SOS Telecom Inc. is recalling Ninja-X dietary supplements because FDA analysis found undeclared sildenafil or its analogs. The product was marketed without an approved NDA or ANDA.
SOS Telecom Inc. is recalling Tiger-X dietary supplements because FDA testing found undeclared sildenafil or analogs. The product was marketed without an approved NDA or ANDA.
SOS Telecom Inc. is recalling Ginseng Power-X capsules because FDA testing found undeclared sildenafil or analogs.
Dream Body Weight Loss is recalling Dream Body Extreme Gold capsules because they contain undeclared sibutramine and were marketed without FDA approval.